Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adaptive Platform Treatment Trial for Outpatients With COVID-19 (Adapt Out COVID)

Trial Profile

Adaptive Platform Treatment Trial for Outpatients With COVID-19 (Adapt Out COVID)

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 20 Apr 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZD 7442 (Primary) ; AZD 7442 (Primary) ; Bamlanivimab (Primary) ; BRII-196 (Primary) ; BRII-198 (Primary) ; Camostat mesilate (Primary) ; Interferon beta-1a (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ACTIV-2; Adapt Out COVID
  • Most Recent Events

    • 22 Mar 2021 Planned End Date changed from 1 Dec 2021 to 1 May 2023.
    • 22 Mar 2021 Planned primary completion date changed from 1 Dec 2021 to 1 May 2023.
    • 19 Mar 2021 Number of treatment arms has been increased form 2 to 10, by the addition of separate arms for 3 different placebo formulations and 5 different drugs/ drug combinations namely- Bamlanivimab, BRII-196/BRII-198, AZD7442 (IM and IV), SNG001 and Camostat. The end-point "Post-treatment presence of SARS-CoV-2 RNA" is removed. The time for onset of symptoms is reduced from 48 to 24 hours, for being included in the study.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top